2017
Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions
Tien CJ, Astrahan MA, Kim JM, Materin M, Chen Z, Nath R, Liu W. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions. Brachytherapy 2017, 16: 1057-1064. PMID: 28778599, DOI: 10.1016/j.brachy.2017.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBrachytherapyEye NeoplasmsHumansIodine RadioisotopesOphthalmoscopyRadiotherapy DosageRadiotherapy Planning, Computer-AssistedTomography, X-Ray ComputedConceptsEye modelDisc distanceDose differenceTumor apexPrescription doseOcular parametersPlaque SimulatorOcular structuresSubstantial dose differencesTarget volumePlaque positionDosimetric parametersPatientsClinical planningDosimetric impactSignificant differencesBrachytherapy planningSeed strengthPlaquesBrachytherapy dose distributionsDose distributionPatient-specific modelsDifferencesTumorsRetina
2011
Experimental characterization of the dosimetric properties of a newly designed I-Seed model AgX100 125I interstitial brachytherapy source
Chen Z, Bongiorni P, Nath R. Experimental characterization of the dosimetric properties of a newly designed I-Seed model AgX100 125I interstitial brachytherapy source. Brachytherapy 2011, 11: 476-482. PMID: 22104352, PMCID: PMC3330133, DOI: 10.1016/j.brachy.2011.08.009.Peer-Reviewed Original Research
2010
Response to “Comment on ‘AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137’” [Med. Phys. 36, 5310–5322 (2009)]
Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y. Response to “Comment on ‘AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137’” [Med. Phys. 36, 5310–5322 (2009)]. Medical Physics 2010, 37: 1933-1933. PMID: 20443515, DOI: 10.1118/1.3358143.Peer-Reviewed Original Research
2007
Silver fluorescent x‐ray yield and its influence on the dose rate constant for nine low‐energy brachytherapy source models
Nath R, Chen ZJ. Silver fluorescent x‐ray yield and its influence on the dose rate constant for nine low‐energy brachytherapy source models. Medical Physics 2007, 34: 3785-3793. PMID: 17985624, DOI: 10.1118/1.2775665.Peer-Reviewed Original Research
2005
Relative Biological Effectiveness of 103Pd and 125I Photons for Continuous Low-Dose-Rate Irradiation of Chinese Hamster Cells
Nath R, Bongiorni P, Chen Z, Gragnano J, Rockwell S. Relative Biological Effectiveness of 103Pd and 125I Photons for Continuous Low-Dose-Rate Irradiation of Chinese Hamster Cells. Radiation Research 2005, 163: 501-509. PMID: 15850411, DOI: 10.1667/rr3363.Peer-Reviewed Original ResearchConceptsContinuous low doseRate irradiationDose-rate effectInverse dose-rate effectCGy/hInitial dose rateChinese hamster lung cellsHigher initial dose rateLow doseHamster lung cellsLung cellsDose rateCell survivalX-ray beamRelative biological effectivenessChinese hamster cellsCellsImplantsAverage RBEHamster cellsBiological responsesBiological effectivenessMonoenergetic X-ray beam
2004
Iodine 125 Versus Palladium 103 Implants for Prostate Cancer
Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 2004, 10: 170-174. PMID: 15285926, DOI: 10.1097/00130404-200405000-00006.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyMinimum tumor doseDisease-free survival ratesComplication rateTumor doseProstate cancerRadiation therapyClinical outcomesPrognostic groupsBiochemical disease-free survival ratesSurvival rateBiochemical disease-free survivalDisease-free survivalHigh complication ratePoor prognostic groupProstate-specific antigenHormonal therapyT stageGleason scoreSingle institutionTransperineal implantationFavorable groupGrade 3Treatment groupsPatientsDevelopment of a rat solid tumor model for continuous low-dose-rate irradiation studies using 125I and 103Pd sources
Nath R, Bongiorni P, Chen Z, Gragnano J, Rockwell S. Development of a rat solid tumor model for continuous low-dose-rate irradiation studies using 125I and 103Pd sources. Brachytherapy 2004, 3: 159-172. PMID: 15533809, DOI: 10.1016/j.brachy.2004.08.004.Peer-Reviewed Original Research
2003
Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives
Chen Z, Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. International Journal Of Radiation Oncology • Biology • Physics 2003, 55: 825-834. PMID: 12573770, DOI: 10.1016/s0360-3016(02)04282-7.Peer-Reviewed Original Research
2002
Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants—a bio-mathematical model
Yue N, Chen Z, Nath R. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants—a bio-mathematical model. Physics In Medicine And Biology 2002, 47: 1185-1204. PMID: 11996063, DOI: 10.1088/0031-9155/47/7/313.Peer-Reviewed Original ResearchConceptsTumor potential doubling timeContinuous low dose rate irradiationTumor cell survivalSeed implantsBio-mathematical modelCell survivalExternal beam radiotherapyPresence of edemaProstate seed implantationLow dose rate irradiationEdema magnitudeEffects of edemaPotential doubling timeTypical edemaDose rate irradiationProstate volumeSurgical traumaPermanent seed implantsSeed implantationSignificant edemaTreatment strategiesSurgical proceduresBeam radiotherapyEdemaDose coverage
2001
Dose rate constant and energy spectrum of interstitial brachytherapy sources
Chen Z, Nath R. Dose rate constant and energy spectrum of interstitial brachytherapy sources. Medical Physics 2001, 28: 86-96. PMID: 11213926, DOI: 10.1118/1.1333748.Peer-Reviewed Original Research
2000
Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution
Chen Z, Yue N, Wang X, Roberts K, Peschel R, Nath R. Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution. International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1405-1419. PMID: 10889396, DOI: 10.1016/s0360-3016(00)00549-6.Peer-Reviewed Original ResearchDosimetric effects of needle divergence in prostate seed implant using and radioactive seeds
Nath S, Chen Z, Yue N, Trumpore S, Peschel R. Dosimetric effects of needle divergence in prostate seed implant using and radioactive seeds. Medical Physics 2000, 27: 1058-1066. PMID: 10841410, DOI: 10.1118/1.598971.Peer-Reviewed Original ResearchConceptsMinimum target doseIodine-125 implantsTarget doseDose coverageTumor biological effective doseTarget dose coverageBiological effective doseBase of prostateRadioactive seedsProstate seed implantsProstate seedPalladium-103Target volumeEffective doseDosimetric qualityDosePatient implantsDosimetric effectsSeed implantsProstateImplantsMagnitude of degradationActual implantationNeedle orientationActual configuration
1999
Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implants
Yue N, Chen Z, Peschel R, Dicker A, Waterman F, Nath R. Optimum timing for image-based dose evaluation of 125I and 103Pd prostate seed implants. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 1063-1072. PMID: 10571216, DOI: 10.1016/s0360-3016(99)00282-5.Peer-Reviewed Original ResearchConceptsDose-volume histogramsProstate volumeDose coverageConventional dose-volume histogramsSeed implantsEdema magnitudeMagnitude of edemaOptimum timingPostimplant dose-volume histogramDose evaluationOptimal patient managementProstate seed implantationPreimplant planImplant patientsPermanent brachytherapy implantsProstate seed implantsPatient managementProstate cancerSeed implantationSurgical proceduresEdemaProstateDose distributionDays postimplantationPatientsLong‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer